stockrowOrgenesis Inc.
ORGS Healthcare Biotechnology
Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023.
- Revenue
- +82.4%
- EPS
- −104.5%
- Free cash flow
- −317.9%
Quarter to December 2024, against a year earlier
Follow ORGS
Alert me
Orgenesis Inc. (ORGS) EV/Sales
As of 6 November 2026, Orgenesis Inc. (ORGS) trades at a EV/Sales of 16.9×. Over the past ten years it has ranged from −6.1× (April 2020) to 91.8× (March 2024); the current reading is higher than 79% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 23.2× | (65.94%) |
| FY2023 | 68.0× | 3,930.51% |
| FY2022 | 1.7× | (19.86%) |
| FY2021 | 2.1× | (73.92%) |
| FY2020 | 8.1× | (63.63%) |
| FY2019 | 22.2× | 772.92% |
| FY2018 | 2.5× | (47.18%) |
| FY2018 | 4.8× | (29.38%) |
| FY2017 | 6.8× | 15.46% |
| FY2017 | 5.9× | (20.87%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 23.2× | (40.60%) |
| Sep 2024 | 39.0× | (26.78%) |
| Jun 2024 | 53.2× | (37.04%) |
| Mar 2024 | 84.5× | 24.38% |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. compare | −71.4× |
| APRE Aprea Therapeutics, Inc. compare | −34.8× |
| EVGN Evogene Ltd. compare | −3.6× |
| LGVN Longeveron Inc. compare | −3.1× |
| CRIS Curis, Inc. compare | −0.3× |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| XCUR Exicure, Inc. compare | 0.2× |
| ORGS Orgenesis Inc. | 16.9× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)